Randomized Study of Intravenous Immunoglobulin in Patients With Mild or Moderate Myasthenia Gravis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00004682|
Recruitment Status : Terminated
First Posted : February 25, 2000
Last Update Posted : March 25, 2015
I. Determine whether intravenous immunoglobulin is an effective therapy for patients with mild or moderate myasthenia gravis.
|Condition or disease||Intervention/treatment||Phase|
|Myasthenia Gravis||Drug: immune globulin||Not Applicable|
PROTOCOL OUTLINE: This study is a randomized, blinded, controlled study. Patients are stratified in both groups according to prior thymectomy (yes vs no) and by Quantitative Myasthenia Gravis Score (equal to or less than 10 vs greater than 10) so that equal numbers are assigned to each group. Patients in group 2 are also stratified as to whether they are currently on azathioprine.
Patients are randomized to receive either intravenous immunoglobulin (IVIG) for 2 days or 5% albumin (the placebo) for 2 days. A second infusion of IVIG for 1 day or albumin placebo for 1 day is given on day 22.
At the end of 6 weeks, after the randomized study, patients may choose to receive 3 additional IVIG infusions.
Patients are followed on days 1, 21, 32, and 42 of randomized or open label study.
Completion date provided represents the completion date of the grant per OOPD records
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||100 participants|
|Study Start Date :||March 1995|
|Study Completion Date :||March 1999|
U.S. FDA Resources
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00004682
|Study Chair:||Richard J. Barohn||University of Texas|